Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases. 

The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation.

Please click here to read the full story